Analysis and occurrence of adverse events with oral anticoagulant therapy

被引:10
作者
Schenk, JF [1 ]
Mörsdorf, S
Pindur, G
Munter, KH
Thrun, F
Tiaden, JD
Wenzel, E
机构
[1] Univ Saarlandes Clin, Dept Clin Hemostaseol & Transfus Med, D-66421 Homburg, Germany
[2] Drug Commiss German Med Profess, Cologne, Germany
关键词
oral anticoagulation; adverse events; Saarland-Model; spontaneous report system; Phoenix database; bleeding;
D O I
10.1055/s-2007-996426
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The antithrombotic potential of oral anticoagulants is undisputed as the frequency of recurrent thrombosis is high unless anticoagulant therapy is continued after hospital discharge. However, the relationship between potency and/or changes in anticoagulant therapy and frequency of complications remains unclear. Optimizing the clinical management of oral anticoagulation information obtained by databases may be advantageous in addition to meeting safety criteria, as described in the "Saarland Model." The Phoenix-database implicates an association between bleeding complications and the hypertensive elderly. From 1968 to 1993 most reports about cerebral/intraspinal bleedings occurred at prothrombin (PT)-values below 20% in the elder patients (>60 years of age) (12%; 367 reports). In the Saarland Model, 60 patients were followed from our department during a 3-year period, Our findings suggest neither a correlation of the range of PT values and the bleeding events nor an association with age or hypertension. It became obvious that "stable phases" of International Normalized Ratio (INR) [+/-15% change of 4 serial controls using nearly constant weekly oral anticoagulant dosages (+/-15%)] might be considered as a valid criterion of safety. At least the individual risk profile determines the patient's fate.
引用
收藏
页码:65 / 71
页数:7
相关论文
共 43 条
[1]  
Adgey AAJ, 1996, HAEMOSTASIS, V26, P237
[2]   COST-EFFECTIVENESS OF MONITORING WARFARIN THERAPY USING STANDARD VERSUS CAPILLARY PROTHROMBIN TIMES [J].
ANSELL, JE ;
HAMKE, AK ;
HOLDEN, A ;
KNAPIC, N .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1989, 91 (05) :587-589
[3]   LONG-TERM PATIENT SELF-MANAGEMENT OF ORAL ANTICOAGULATION [J].
ANSELL, JE ;
PATEL, N ;
OSTROVSKY, D ;
NOZZOLILLO, E ;
PETERSON, AM ;
FISH, L .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (20) :2185-2189
[4]   Hirudin in acute myocardial infarction - Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial [J].
Antman, EM .
CIRCULATION, 1996, 94 (05) :911-921
[5]  
Bata I, 1997, CIRCULATION, V96, P769
[6]  
Betriu A, 1997, NEW ENGL J MED, V336, P1621
[7]   COMPARATIVE SAFETY PROFILES OF HIRULOG AND HEPARIN IN PATIENTS UNDERGOING CORONARY ANGIOPLASTY [J].
BITTL, JA .
AMERICAN HEART JOURNAL, 1995, 130 (03) :658-665
[8]  
Booth SL, 1997, THROMB HAEMOSTASIS, V77, P504
[9]  
BREDDIN H, 1984, ERKRANKUNGEN DURCH A, P310
[10]   THROMBOEMBOLIC AND BLEEDING COMPLICATIONS IN PATIENTS WITH MECHANICAL HEART-VALVE PROSTHESES [J].
CANNEGIETER, SC ;
ROSENDAAL, FR ;
BRIET, E .
CIRCULATION, 1994, 89 (02) :635-641